| HIV Infections
Prezista vs Truvada
Side-by-side clinical, coverage, and cost comparison for hiv infections.Deep comparison between: Prezista vs Truvada with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTruvada has a higher rate of injection site reactions vs Prezista based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Truvada but not Prezista, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Prezista
Truvada
At A Glance
Oral
Once daily or Twice daily
HIV-1 protease inhibitor
Oral
Once daily
NRTI combination (FTC + TDF)
Indications
- HIV Infections
- HIV Infections
Dosing
HIV-1 Infections (treatment-naive adults) Darunavir 800 mg with ritonavir 100 mg once daily, oral, with food
HIV-1 Infections (treatment-experienced adults, no darunavir resistance) Darunavir 800 mg with ritonavir 100 mg once daily, oral, with food
HIV-1 Infections (treatment-experienced adults, at least one darunavir resistance substitution) Darunavir 600 mg with ritonavir 100 mg twice daily, oral, with food
HIV-1 Infections (pregnant patients) Darunavir 600 mg with ritonavir 100 mg twice daily, oral, with food
HIV-1 Infections (pediatric patients, 3 to less than 18 years) Weight-based dosing with ritonavir, oral, with food. Dosage based on body weight and resistance status, not to exceed adult dose
HIV Infections Adults and pediatric patients weighing >=35 kg: one tablet (200 mg FTC/300 mg TDF) once daily orally with or without food; pediatric patients weighing 17 to <35 kg: weight-based lower-strength tablet (100 mg/150 mg, 133 mg/200 mg, or 167 mg/250 mg) once daily; CrCl 30-49 mL/min: one tablet every 48 hours; CrCl <30 mL/min or hemodialysis: not recommended.
HIV-1 Pre-Exposure Prophylaxis HIV-1 uninfected adults and adolescents weighing >=35 kg: one tablet (200 mg FTC/300 mg TDF) once daily orally with or without food; not recommended if CrCl <60 mL/min.
Contraindications
- Co-administration with alfuzosin
- Co-administration with colchicine in patients with renal and/or hepatic impairment
- Co-administration with rifampin
- Co-administration with lurasidone
- Co-administration with pimozide
- Co-administration with dronedarone
- Co-administration with ivabradine
- Co-administration with ranolazine
- Co-administration with ergot derivatives (dihydroergotamine, ergotamine, methylergonovine)
- Co-administration with St. John's wort (Hypericum perforatum)
- Co-administration with elbasvir/grazoprevir
- Co-administration with lomitapide
- Co-administration with lovastatin
- Co-administration with simvastatin
- Co-administration with naloxegol
- Co-administration with sildenafil for pulmonary arterial hypertension
- Co-administration with orally administered midazolam
- Co-administration with triazolam
- Unknown or positive HIV-1 status when used for HIV-1 PrEP
Adverse Reactions
Most common (>=5%, treatment-naive) Diarrhea, headache, abdominal pain, rash, nausea, vomiting
Most common (>=5%, treatment-experienced) Diarrhea, nausea, rash, abdominal pain, vomiting
Serious Hepatotoxicity, severe skin reactions (Stevens-Johnson Syndrome, toxic epidermal necrolysis), acute pancreatitis, diabetes mellitus, hyperglycemia, immune reconstitution syndrome
Postmarketing Rhabdomyolysis, acute generalized exanthematous pustulosis, drug rash with eosinophilia and systemic symptoms, crystal nephropathy, crystalluria
Most common (>=10%) Diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, rash
Serious Severe acute exacerbations of hepatitis B, new onset or worsening renal impairment, immune reconstitution syndrome, bone loss and mineralization defects, lactic acidosis/severe hepatomegaly with steatosis
Postmarketing Allergic reaction including angioedema, lactic acidosis, hypokalemia, hypophosphatemia, dyspnea, pancreatitis, hepatic steatosis, hepatitis, rash, rhabdomyolysis, osteomalacia, muscular weakness, myopathy, acute renal failure, Fanconi syndrome, proximal renal tubulopathy, interstitial nephritis, nephrogenic diabetes insipidus, proteinuria, asthenia
Pharmacology
Darunavir is an HIV-1 protease inhibitor that selectively inhibits cleavage of HIV-1 Gag-Pol polyproteins in infected cells, preventing formation of mature virus particles.
FTC and TDF are both nucleoside analog reverse transcriptase inhibitors (NRTIs); each is converted intracellularly to an active triphosphate form that inhibits HIV-1 reverse transcriptase by competing with natural dNTP substrates and causing chain termination. No antagonism between FTC and TDF has been observed in cell culture combination studies.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Prezista
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Truvada
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Prezista
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Truvada
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Prezista
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Truvada
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PrezistaView full Prezista profile
TruvadaView full Truvada profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.